135 related articles for article (PubMed ID: 12847561)
1. DX-9065a, a direct inhibitor of factor Xa.
Kaiser B
Cardiovasc Drug Rev; 2003; 21(2):91-104. PubMed ID: 12847561
[TBL] [Abstract][Full Text] [Related]
2. Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.
Tobu M; Iqbal O; Ma Q; Schultz C; Jeske W; Hoppensteadt D; Lewis B; Fareed D; Fareed J
Clin Appl Thromb Hemost; 2003 Jan; 9(1):1-17. PubMed ID: 12643318
[TBL] [Abstract][Full Text] [Related]
3. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
Hara T; Yokoyama A; Morishima Y; Kunitada S
Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
[TBL] [Abstract][Full Text] [Related]
4. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers.
Murayama N; Tanaka M; Kunitada S; Yamada H; Inoue T; Terada Y; Fujita M; Ikeda Y
Clin Pharmacol Ther; 1999 Sep; 66(3):258-64. PubMed ID: 10511061
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
[TBL] [Abstract][Full Text] [Related]
6. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis.
Rogers KL; Chi L; Rapundalo ST; Kramer JB; Gallagher KP
Basic Res Cardiol; 1999 Feb; 94(1):15-22. PubMed ID: 10097826
[TBL] [Abstract][Full Text] [Related]
7. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
Alexander JH; Dyke CK; Yang H; Becker RC; Hasselblad V; Zillman LA; Kleiman NS; Hochman JS; Berger PB; Cohen EA; Lincoff AM; Saint-Jacques H; Chetcuti S; Burton JR; Buergler JM; Spence FP; Shimoto Y; Robertson TL; Kunitada S; Bovill EG; Armstrong PW; Harrington RA;
J Thromb Haemost; 2004 Feb; 2(2):234-41. PubMed ID: 14995984
[TBL] [Abstract][Full Text] [Related]
8. A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor induced disseminated intravascular coagulation in rats.
Tanabe K; Terada Y; Shibutani T; Kunitada S; Kondo T
Thromb Res; 1999 Oct; 96(2):135-43. PubMed ID: 10574591
[TBL] [Abstract][Full Text] [Related]
9. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
Herbert JM; Bernat A; Dol F; Hérault JP; Crépon B; Lormeau JC
J Pharmacol Exp Ther; 1996 Mar; 276(3):1030-8. PubMed ID: 8786532
[TBL] [Abstract][Full Text] [Related]
10. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
Rezaie AR
Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
[TBL] [Abstract][Full Text] [Related]
11. A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats.
Kaiser B; Paintz M; Scholz O; Kunitada S; Fareed J
Thromb Res; 2000 Apr; 98(2):175-85. PubMed ID: 10713319
[TBL] [Abstract][Full Text] [Related]
12. In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft.
Kim DI; Kambayashi J; Shibuya T; Sakon M; Kawasaki T
J Atheroscler Thromb; 1996; 2(2):110-6. PubMed ID: 9225218
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of gastrointestinal absorption of DX-9065a, a new synthetic anticoagulant.
Fujii Y; Takahashi M; Morita H; Kikuchi H; Aramaki Y; Amidon GL
Drug Metab Pharmacokinet; 2007 Feb; 22(1):26-32. PubMed ID: 17329908
[TBL] [Abstract][Full Text] [Related]
14. DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa.
Matsushita K; Imamura T; Tomikawa M; Tancharoen S; Tatsuyama S; Maruyama I
J Periodontal Res; 2006 Apr; 41(2):148-56. PubMed ID: 16499718
[TBL] [Abstract][Full Text] [Related]
15. Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats.
Chino D; Fujita Y; Ishii K; Nakayama K
J Pharmacol Sci; 2003 Apr; 91(4):319-29. PubMed ID: 12719661
[TBL] [Abstract][Full Text] [Related]
16. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
Dyke CK; Becker RC; Kleiman NS; Hochman JS; Bovill EG; Lincoff AM; Gerstenblith G; Dzavik V; Gardner LH; Hasselblad V; Zillman LA; Shimoto Y; Robertson TL; Kunitada S; Armstrong PW; Harrington RA
Circulation; 2002 May; 105(20):2385-91. PubMed ID: 12021225
[TBL] [Abstract][Full Text] [Related]
17. A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver.
Yamaguchi Y; Okabe K; Liang J; Matsumura F; Ohshiro H; Ishihara K; Matsuda T; Takeya M; Kuratsu JI; Mori K; Yamada S; Ogawa M
Dig Dis Sci; 1999 Dec; 44(12):2568-76. PubMed ID: 10630515
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
[TBL] [Abstract][Full Text] [Related]
19. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats.
Yamazaki M; Asakura H; Aoshima K; Saito M; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Ikeda T; Matsuda T
Thromb Haemost; 1994 Sep; 72(3):392-6. PubMed ID: 7855790
[TBL] [Abstract][Full Text] [Related]
20. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Graff J; Picard-Willems B; Harder S
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
